Specifically, this study is unique in its integration of multiple immune cell-specific immunohistochemistry (CD8, CD4, CD20, and CD163) with published immune gene expression signatures, including the IRIS gene sets, which we recently demonstrated can effectively interrogate the breast cancer tumor immune microenvironment in a large clinical trial [33]. The gene discussed is CD163; the disease is neoplasm.